Prospective, Multicenter, Phase II Study on Reducing the Dosage of Idarubicin and FLAG for Patients Younger than 65 Years with Resistant Acute Myeloid Leukemia: A Comparison with a Higher Dosage Trial

Publisher： Karger

E-ISSN： 1421-9662|132|1|87-96

ISSN： 0001-5792

Source： Acta Haematologica, Vol.132, Iss.1, 2014-02, pp. : 87-96

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 9, 2015-09 ,pp. : 796-799

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : 276-281

John Wiley & Sons Inc

Access to resources Recommend Favorite

Recombinant interleukin‐2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1010-1017

John Wiley & Sons Inc

Access to resources Recommend Favorite

The demarcation between younger and older acute myeloid leukemia patients: A pooled analysis of 3 prospective studies

By  

CANCER, Vol. 119, Iss. 18, 2013-09 ,pp. : 3326-3333

John Wiley & Sons Inc

Access to resources Recommend Favorite

Nonbiological factors affecting survival in younger patients with acute myeloid leukemia

By  

CANCER, Vol. 121, Iss. 21, 2015-11 ,pp. : 3877-3884

John Wiley & Sons Inc

Access to resources Recommend Favorite